Stephen V Liu: Huge potential utility of LB for early stage lung cancer explained by Christian Rolfo

Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared on X:

“Huge potential utility of liquid biopsy for early stage lung cancer including assessing MRD, as explained by Dr. Christian Rolfo at DC Lung 2024. Amazing progress from an analytic standpoint expertly outlined.”

More posts featuring Stephen V Liu and Christian Rolfo on oncodaily.com

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.

His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.

Christian Rolfo MD, PhD, MBA, is the Division Director of Medical Oncology and Associate Director for Early Phase Clinical Trials at The James Comprehensive Cancer Center, The Ohio State University. He also serves as a Professor of Internal Medicine -Oncology at Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute. He has authored over 350 scientific articles & contributions to book chapters